IAVI Report

IAVI Report Collage As of 2026, IAVI has decided to cease its publication due to budget constraints that it and many other global public health- non-profit organizations are now facing. It is sad to see this publication, with its rich history tracking HIV prevention research and many other public-health-related stories, end. Over the 30 years since its inception, IAVI Report has evolved from a more IAVI-centered newsletter to a full-color journal on HIV science and prevention research, to an online-only publication. Its shorter-lived, sister journal VAX, was a resource for clinical trial sites involved in HIV research and to inform communities more broadly about HIV research and the science of other infectious diseases. Throughout this history, a talented and dedicated staff of writers, production managers, advisors, and copyeditors, as well as a stable of gifted freelance writers, sought out and brought to you, our readers, the most interesting and important stories in the field. I was privileged to work alongside many of them in the nearly 20 years I’ve worked with IAVI, and I am grateful for all they taught me and all the great work they did. I am also grateful to the people who are doing this work across the globe for sharing their stories and for being such a source of light. I wrote an article last month on the resilience of African HIV vaccine researchers who are facing devastating budget cuts following the decimation of USAID. It was but one example of the inspiring people I’ve interacted with on my journey from staff writer to managing editor of IAVI Report. It is also one of numerous articles that capture the perseverance and enthusiasm of the scientists, clinicians, nurses, advocates, activists, and communities that are applying science to improve the lives of everyone, everywhere. Whether it was interviewing scientists at the U.S. National Institute of Allergy and Infectious Diseases, attending conferences, or visiting HIV vaccine clinical trial sites, I was repeatedly inspired and motivated by the science, ingenuity, and humanity I saw on full display. These stories remind me of why I became a science writer. And now, with science under attack in some political circles, it reminds me why science writing and effective communication are more important than ever. Thank you for staying with us for 30 years, for believing in this work, and for continuing it even after IAVI Report ends. Our final article is a tribute to IAVI Report and a reminder of the optimism, determination, and passion that have, and always will, fuel progress.

Reflecting on nearly three decades of IAVI Report and the future of HIV vaccine research.

Drastic cuts to U.S. government funding imperil HIV/AIDS treatment and prevention programs and threaten HIV vaccine and cure research efforts across Africa. But the overarching view from East African researchers is one of resilience, not defeat.

An HIV vaccine academy showcases the scientific talent of African researchers but is tempered by funding worries

The U.S. National Institute of Allergy and Infectious Diseases cancels funding for two consortia orchestrating HIV vaccine development efforts, leaving the field in peril.

Funding, staffing, and policy changes by the U.S. government trigger a major blow to vaccine research and international collaborations that were decades in the making.

Adam Ratner discusses his new book on measles and what it foretells about the future of public health.

The 7th Global Forum on TB Vaccines stoked optimism but raised questions about how the field can optimize efforts to introduce new vaccines this decade.

Vaccines against deadly microbial pathogens could put a dent in antimicrobial resistance.

Quarraisha and Salim Abdool Karim received the Lasker Prize for public service in recognition of their decades-spanning work on HIV prevention, treatment, and advocacy.

Discovery medicine trials are underway to evaluate several HIV vaccine immunogens designed to prime the immune system to make broadly neutralizing antibodies. What comes next?

Manufacturing proteins is notoriously expensive and complex. Will new ways of producing them come from continuous processes, Sunflowers, or even…goat milk?